## 2025 Hematology/Oncology Professional Education (HOPE)

# 2025 Hematology/Oncology Professional Education (HOPE)-Navigating the Use of Targeted Therapy in Colorectal Cancer - 11/4/2025

11/04/2025 at 03:00 PM to 11/04/2025 at 04:00 PM

Live Activity

## **Purpose:**

This series provides hematology/oncology-related education to healthcare professionals caring for patients with cancer. This series will bring members of the healthcare team together to discuss new medication, clinical trial data, guideline updates, and disease state managements for various malignancies.

## **Objectives:**

- 11. Define the epidemiology and etiology of colorectal cancer and the common mutations that may occur.
- 2 2. Review the current guideline recommendations for the use of targeted therapies in the treatment of colorectal cancer.
- 3 3. Describe the recent clinical data supporting the use of targeted therapies and their potential clinical impact.

## **Target Audience:**

Physician, Nurse - RN, Pharmacist, Pharmacy Technician, Medical Assistants, Nurse - Nurse Practitioner, Physician Assistant, Nurse - LPN/LVN

## For successful completion:

- Attend education
- Complete evaluation

## **Accreditation & Credit Designation:**

#### **Accreditation**



JOINTLY ACCREDITED PROVIDER™

In support of improving patient care, Avera is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

#### Continuing Education Credit Designation(s)



**IPCE (Team-based):** This activity was planned by and for the healthcare team, and learners will receive 1.00 IPCE credit(s) for learning and change.

**Medicine CME:** Avera designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)* $^{\text{TM}}$ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

**REMINDER** 

Attendance can be texted up to 24 hours after the activity





**Nurse CE:** Avera designates this activity for a maximum of 1.00 ANCC contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

#### **Nursing Pharmacotherapeutic**

This activity has been approved for 1.00 pharmacotherapeutic credit(s).

Pharmacy CE: Avera designates this activity for 1.00 ACPE contact hour(s). Pharmacists and pharmacy technicians should claim only the credit commensurate with the extent of their participation in the activity. Credit will be uploaded to the NABP CPE Monitor® within 30 days after the activity completion. Per ACPE rules, Avera does not have access nor the ability to upload credits requested after the evaluation closes. It is the responsibility of the pharmacist or pharmacy technician to provide the correct information (NABP ID and DOB (MMDD)) to receive credit.

**Medical Assistant:** This program has been granted prior approval by the American Association of Medical Assistants (AAMA) for 1.00 continuing education unit(s). Granting approval in no way constitutes endorsement by the AAMA of the program content or the program provider. Attendance for this activity will be submitted directly to the AAMA.

## **Additional Information:**

Feedback person for this educational activity is: kyle.laporte@avera.org

## **Disclosure Policy:**

Due to the regulations required for CE credits, all conflicts of interest that persons in a position to control or influence the education must be fully disclosed to participants. In observance of this requirement, we are providing the following disclosure information: all relevant financial relationships disclosed below have been mitigated.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Heidi McKean, MD	Content Expert - Committee Member	Nothing to disclose - 08/09/2025
Jacob Hobbs, PharmD, BCOP	Content Expert - Committee Member, Faculty	Advisor-AstraZeneca (Relationship has ended) - 10/24/2025
KATHERINE REHFELDT, RN	Content Expert - Committee Member	Nothing to disclose - 10/27/2025
Kyle 6334 LaPorte, PharmD	Lead Planner	Nothing to disclose - 08/07/2025
Waqas Jehangir, MD	Content Expert - Committee Member	Nothing to disclose - 08/07/2025



**REMINDER** 

